Laboratorios Farmaceuticos ROVI (ROVI) — Working Capital to Net Assets Ratio
Laboratorios Farmaceuticos ROVI (ROVI) has a Working Capital to Net Assets ratio of 59.1% as of September 2025. Working capital of €373.77 Million (current assets of €559.19 Million minus current liabilities of €185.42 Million) is measured against net assets of €632.80 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Laboratorios Farmaceuticos ROVI (ROVI) liquidity interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Laboratorios Farmaceuticos ROVI Working Capital to Net Assets (2004–2024)
This chart shows how Laboratorios Farmaceuticos ROVI's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2004 to 2024. As of September 2025, the ratio stands at 59.1%, reflecting working capital of €373.77 Million against net assets of €632.80 Million EUR. For the complete balance sheet picture, see ROVI current and non-current assets.
Annual Working Capital to Net Assets for Laboratorios Farmaceuticos ROVI (2004–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Laboratorios Farmaceuticos ROVI from 2004 to 2024, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Laboratorios Farmaceuticos ROVI liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 57.6% | €334.92 Million | €581.54 Million | €491.57 Million | €156.65 Million | ▲ +0.6 pp |
| 2023 | 56.9% | €309.49 Million | €543.49 Million | €509.33 Million | €199.84 Million | ▼ -6.2 pp |
| 2022 | 63.1% | €329.19 Million | €521.38 Million | €623.07 Million | €293.89 Million | ▼ -4.0 pp |
| 2021 | 67.1% | €315.97 Million | €470.98 Million | €506.36 Million | €190.39 Million | ▲ +2.4 pp |
| 2020 | 64.7% | €241.69 Million | €373.70 Million | €364.58 Million | €122.89 Million | ▼ -0.8 pp |
| 2019 | 65.5% | €211.18 Million | €322.39 Million | €317.88 Million | €106.71 Million | ▲ +7.6 pp |
| 2018 | 57.9% | €166.49 Million | €287.47 Million | €254.00 Million | €87.51 Million | ▲ +8.4 pp |
| 2017 | 49.5% | €94.94 Million | €191.69 Million | €168.17 Million | €73.22 Million | ▲ +0.1 pp |
| 2016 | 49.4% | €90.63 Million | €183.41 Million | €167.07 Million | €76.44 Million | ▼ -8.1 pp |
| 2015 | 57.6% | €94.86 Million | €164.78 Million | €154.08 Million | €59.23 Million | ▼ -5.5 pp |
| 2014 | 63.1% | €99.92 Million | €158.47 Million | €162.03 Million | €62.12 Million | ▲ +8.3 pp |
| 2013 | 54.8% | €79.14 Million | €144.46 Million | €137.48 Million | €58.34 Million | ▼ -5.2 pp |
| 2012 | 60.0% | €75.91 Million | €126.45 Million | €131.04 Million | €55.13 Million | ▼ -38.6 pp |
| 2011 | 98.6% | €112.42 Million | €113.98 Million | €169.18 Million | €56.76 Million | ▼ -7.3 pp |
| 2010 | 105.9% | €110.30 Million | €104.13 Million | €161.93 Million | €51.63 Million | ▲ +11.2 pp |
| 2009 | 94.7% | €67.71 Million | €71.50 Million | €131.46 Million | €63.75 Million | ▲ +29.5 pp |
| 2008 | 65.2% | €31.59 Million | €48.44 Million | €78.64 Million | €47.06 Million | ▼ -23.0 pp |
| 2007 | 88.2% | €45.79 Million | €51.92 Million | €80.31 Million | €34.52 Million | ▲ +23.0 pp |
| 2006 | 65.2% | €16.83 Million | €25.81 Million | €53.73 Million | €36.90 Million | ▲ +29.5 pp |
| 2005 | 35.7% | €1.72 Trillion | €4.80 Trillion | €5.07 Trillion | €3.35 Trillion | ▼ -60682.3 pp |
| 2004 | 60718.1% | €1.77 Billion | €2.92 Million | €5.40 Billion | €3.63 Billion | — |